Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.verified

NTLA

Price:

$20.24

Market Cap:

$1.95B

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Reg...[Read more]

Industry

Biotechnology

IPO Date

2016-05-06

Stock Exchange

NASDAQ

Ticker

NTLA

The PE Ratio as of April 2024 (TTM) for Intellia Therapeutics, Inc. (NTLA) is -3.73

According to Intellia Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.73. This represents a change of -44.90% compared to the average of -6.77 of the last 4 quarters.

Intellia Therapeutics, Inc. (NTLA) Historical PE Ratio (quarterly & annually)

How has NTLA PE Ratio performed in the past?

The mean historical PE Ratio of Intellia Therapeutics, Inc. over the last ten years is -13.29. The current -3.73 PE Ratio has changed 2.71% with respect to the historical average. Over the past ten years (40 quarters), NTLA's PE Ratio was at its highest in in the March 2020 quarter at -4.85. The PE Ratio was at its lowest in in the March 2015 quarter at -89.29.

Quarterly (TTM)
Annual

Average

-13.29

Median

-8.34

Minimum

-32.28

Maximum

0

Intellia Therapeutics, Inc. (NTLA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Intellia Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 224.39%

Maximum Annual PE Ratio = 0

Minimum Annual Increase = -Infinity%

Minimum Annual PE Ratio = -32.28

Quarterly (TTM)
Annual
YearPE RatioChange
2023-5.622.67%
2022-5.48-83.03%
2021-32.2833.07%
2020-24.26224.39%
2019-7.488.54%
2018-6.89-32.77%
2017-10.2511.25%
2016-9.21-70.75%
2015-31.49-Infinity%

Intellia Therapeutics, Inc. (NTLA) Average PE Ratio

How has NTLA PE Ratio performed in the past?

The current PE Ratio of Intellia Therapeutics, Inc. (NTLA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-14.46

5-year avg

-15.02

10-year avg

-13.29

Intellia Therapeutics, Inc. (NTLA) PE Ratio vs. Peers

How is NTLA’s PE Ratio compared to its peers?

Intellia Therapeutics, Inc.’s PE Ratio is less than Editas Medicine, Inc. (-2.83), less than Caribou Biosciences, Inc. (-3.38), greater than CRISPR Therapeutics AG (-27.65), less than Verve Therapeutics, Inc. (-2.21), greater than Beam Therapeutics Inc. (-14.50), less than Fate Therapeutics, Inc. (-2.64), less than Vertex Pharmaceuticals Incorporated (28.49), less than Ginkgo Bioworks Holdings, Inc. (-1.81), less than Prime Medicine, Inc. (-2.17), greater than Sana Biotechnology, Inc. (-5.94),

Build a custom stock screener for Intellia Therapeutics, Inc. (NTLA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Intellia Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Intellia Therapeutics, Inc. (NTLA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Intellia Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Intellia Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Intellia Therapeutics, Inc. (NTLA)?

What is the highest PE Ratio for Intellia Therapeutics, Inc. (NTLA)?

What is the 3-year average PE Ratio for Intellia Therapeutics, Inc. (NTLA)?

What is the 5-year average PE Ratio for Intellia Therapeutics, Inc. (NTLA)?

How does the current PE Ratio for Intellia Therapeutics, Inc. (NTLA) compare to its historical average?